TY - JOUR
T1 - Relaxin receptors in hepatic stellate cells and cirrhotic liver
AU - Bennett, Robert G.
AU - Dalton, Shana R.
AU - Mahan, Katrina J.
AU - Gentry-Nielsen, Martha J.
AU - Hamel, Frederick G.
AU - Tuma, Dean J.
N1 - Funding Information:
This work was supported by funding from the VA Merit Review Program (R.G.B., M.J.G., D.J.T.) and the Bly Memorial Research Fund (R.G.B.). We thank Dr. Richard Tobin for his support of this project.
PY - 2007/4/1
Y1 - 2007/4/1
N2 - The polypeptide hormone relaxin has antifibrotic effects on a number of tissues, including the liver. Central to the progression of hepatic fibrosis is the transdifferentiation of hepatic stellate cells (HSC) from a quiescent state to an activated, myofibroblastic phenotype that secretes fibrillar collagen. Relaxin inhibits markers of HSC activation, but relaxin receptor expression in the liver is unclear. The purpose of this study was to determine the expression of the relaxin receptors LGR7 and LGR8 in activated HSC. Production of cAMP was induced by treatment of HSC with relaxin, or the relaxin-related peptides InsL3 or relaxin-3, selective activators of LGR8 and LGR7, respectively. Quiescent HSC expressed low levels of LGR7 but not LGR8. During progression to the activated phenotype, expression of both receptors increased markedly. Immunocytochemistry confirmed the presence of both receptors in activated HSC. In normal rat liver, LGR7, but not LGR8, was expressed at low levels. In cirrhotic liver, expression of both receptors significantly increased. Neither receptor was detectable in normal liver by immunohistochemistry, but both LGR7 and LGR8 were readily detectable in cirrhosis. These results were confirmed in human cirrhotic tissue, with the additional finding of occasional perisinusoidal LGR7 immunoreactivity in non-cirrhotic tissue. In conclusion, the expression of LGR7 and LGR8 is increased with activation of HSC in culture. Cirrhosis also caused increased expression of both receptors. Therefore, agents that stimulate LGR8 and LGR7 may be therapeutically useful to limit the activation of hepatic stellate cells in liver injury.
AB - The polypeptide hormone relaxin has antifibrotic effects on a number of tissues, including the liver. Central to the progression of hepatic fibrosis is the transdifferentiation of hepatic stellate cells (HSC) from a quiescent state to an activated, myofibroblastic phenotype that secretes fibrillar collagen. Relaxin inhibits markers of HSC activation, but relaxin receptor expression in the liver is unclear. The purpose of this study was to determine the expression of the relaxin receptors LGR7 and LGR8 in activated HSC. Production of cAMP was induced by treatment of HSC with relaxin, or the relaxin-related peptides InsL3 or relaxin-3, selective activators of LGR8 and LGR7, respectively. Quiescent HSC expressed low levels of LGR7 but not LGR8. During progression to the activated phenotype, expression of both receptors increased markedly. Immunocytochemistry confirmed the presence of both receptors in activated HSC. In normal rat liver, LGR7, but not LGR8, was expressed at low levels. In cirrhotic liver, expression of both receptors significantly increased. Neither receptor was detectable in normal liver by immunohistochemistry, but both LGR7 and LGR8 were readily detectable in cirrhosis. These results were confirmed in human cirrhotic tissue, with the additional finding of occasional perisinusoidal LGR7 immunoreactivity in non-cirrhotic tissue. In conclusion, the expression of LGR7 and LGR8 is increased with activation of HSC in culture. Cirrhosis also caused increased expression of both receptors. Therefore, agents that stimulate LGR8 and LGR7 may be therapeutically useful to limit the activation of hepatic stellate cells in liver injury.
KW - Fibrosis
KW - InsL3
KW - LGR7
KW - LGR8
KW - Relaxin-3
UR - http://www.scopus.com/inward/record.url?scp=33847156731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847156731&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2006.12.007
DO - 10.1016/j.bcp.2006.12.007
M3 - Article
C2 - 17214975
AN - SCOPUS:33847156731
SN - 0006-2952
VL - 73
SP - 1033
EP - 1040
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 7
ER -